<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:43:03Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7251680" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7251680</identifier>
        <datestamp>2020-06-04</datestamp>
        <setSpec>trials</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Trials</journal-id>
              <journal-id journal-id-type="iso-abbrev">Trials</journal-id>
              <journal-title-group>
                <journal-title>Trials</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1745-6215</issn>
              <publisher>
                <publisher-name>BioMed Central</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7251680</article-id>
              <article-id pub-id-type="pmcid">PMC7251680</article-id>
              <article-id pub-id-type="pmc-uid">7251680</article-id>
              <article-id pub-id-type="pmid">32460885</article-id>
              <article-id pub-id-type="publisher-id">4354</article-id>
              <article-id pub-id-type="doi">10.1186/s13063-020-04354-7</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Study Protocol</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinsonâ€™s disease: a study protocol for a randomised controlled trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Sackley</surname>
                    <given-names>C. M.</given-names>
                  </name>
                  <address>
                    <email>catherine.sackley@kcl.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes" equal-contrib="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7713-9834</contrib-id>
                  <name>
                    <surname>Rick</surname>
                    <given-names>C.</given-names>
                  </name>
                  <address>
                    <email>caroline.rick@nottingham.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Au</surname>
                    <given-names>P.</given-names>
                  </name>
                  <address>
                    <email>P.Au@bham.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Brady</surname>
                    <given-names>M. C.</given-names>
                  </name>
                  <address>
                    <email>M.Brady@gcu.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Beaton</surname>
                    <given-names>G.</given-names>
                  </name>
                  <address>
                    <email>Gillian.Beaton@ggc.scot.nhs.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Burton</surname>
                    <given-names>C.</given-names>
                  </name>
                  <address>
                    <email>chris.burton@canterbury.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Caulfield</surname>
                    <given-names>M.</given-names>
                  </name>
                  <address>
                    <email>m.caulfield@bangor.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dickson</surname>
                    <given-names>S.</given-names>
                  </name>
                  <address>
                    <email>Sylvia.Dickson@gcu.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dowling</surname>
                    <given-names>F.</given-names>
                  </name>
                  <address>
                    <email>francis.dowling@addenbrookes.nhs.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff9">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hughes</surname>
                    <given-names>M.</given-names>
                  </name>
                  <address>
                    <email>M.Hughes@bham.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ives</surname>
                    <given-names>N.</given-names>
                  </name>
                  <address>
                    <email>n.j.ives@bham.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jowett</surname>
                    <given-names>S.</given-names>
                  </name>
                  <address>
                    <email>s.jowett@bham.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff10">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Masterson-Algar</surname>
                    <given-names>P.</given-names>
                  </name>
                  <address>
                    <email>p.m.algar@bangor.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nicoll</surname>
                    <given-names>A.</given-names>
                  </name>
                  <address>
                    <email>Avril.Nicoll@gcu.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Patel</surname>
                    <given-names>S.</given-names>
                  </name>
                  <address>
                    <email>s.a.patel@bham.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Smith</surname>
                    <given-names>C. H.</given-names>
                  </name>
                  <address>
                    <email>christina.smith@ucl.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff11">11</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Woolley</surname>
                    <given-names>R.</given-names>
                  </name>
                  <address>
                    <email>r.l.woolley.1@bham.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Clarke</surname>
                    <given-names>C. E.</given-names>
                  </name>
                  <address>
                    <email>carlclarke@nhs.net</email>
                  </address>
                  <xref ref-type="aff" rid="Aff12">12</xref>
                  <xref ref-type="aff" rid="Aff13">13</xref>
                </contrib>
                <contrib contrib-type="author">
                  <collab>on behalf of the PD COMM Collaborative Group<contrib-group><contrib contrib-type="author"><name><surname>Church</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Davey</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gallagher</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Conroy</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bailey</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Done</surname><given-names>B.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Davies</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sveinbjornsdottir</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kasti</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Allen</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Colnet</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Riches</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kittridge</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Morris</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Waszkiewicz</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lyell</surname><given-names>V.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Page</surname><given-names>V.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bassford</surname><given-names>N.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rayner</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Henderson</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Abraham</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hindle</surname><given-names>J. V.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Martin-Forbes</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Watkins</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Roberts</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Newcombe</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bibby</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Matthews</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Roberts</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hawthorne</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Clewley</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lord</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Roberts</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bretag</surname><given-names>G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Noble</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>McGhee</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mcclure</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Teo</surname><given-names>A. Ling Zhi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wheeldon</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wilkinson</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Oprea</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Van Duyvenvoorde</surname><given-names>G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wilson</surname><given-names>N.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Evans</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Belshaw</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Clarke</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Turner</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Thompson</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Saha</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Aram</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mullan</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Newman</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Micabel</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Robinson</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Chick</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gaylard</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cochrane</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>E. C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kissick</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wright</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mohamed</surname><given-names>B.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mahon</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Williams</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Appleton</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Elliott</surname><given-names>N.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Evans</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ridley</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Funaki</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Daly</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hackworth</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Timms</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Evison</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bajracharya</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Silverdale</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Andrews</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Davies</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bedford</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mournfield</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Howieson</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Price</surname><given-names>V.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hunter</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Baggs</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Evans</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Norton</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Holland</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pointon</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kulkarni</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bobeldijk</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Beames</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cavanagh</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sudlow</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lennox</surname><given-names>G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Whittaker</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nelson</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pegler</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Drayson</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Turner</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Stockwell</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Andrews</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>White</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Turner</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Burnay</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hickey</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Warner</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Buccoliero</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Isles</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Stemp</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Guy</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bennett</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Randall</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ware</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cann</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sautin</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Grobler</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Adjei</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hankin</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ovayolu</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dobbs</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Joyce</surname><given-names>O.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Humphreys</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jha</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Holbrook</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rowsell</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Thornley</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Conway</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>James</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Murrow</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hughes</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pope</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>MacPhee</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Williams</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hughes</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Evans</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Richmond</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pilborough</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Campbell</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Davies</surname><given-names>S. E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Asandei</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Majeed</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dawber</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Furey</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Oppetit</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Birt</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hare</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fleming</surname><given-names>V.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Timoroksa</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Al-Nufoury</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sharp</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Freimann</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mavroudis</surname><given-names>I.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Alty</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Richfield</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Harrison</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>V.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Joyce</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bamford</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jamieson</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cosgrove</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Butterworth</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sacre</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Makawa</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Duggan-Carter</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Arnold</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Brown</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mpofu</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Joyce</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Henderson</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wiseman</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hyne</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Stevens</surname><given-names>B.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wood</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Holland</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>V.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Juada</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Molloy</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pavel</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dhanarante</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Adedoyin</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rowbottom</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Little</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Choudhury</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Prados</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kelly</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Eggers</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Saifee</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Poku</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Niepage</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ahearn</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fountain</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Curran</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Watt</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wilson</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Anderson</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Graham</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hewat</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Donaldson</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Moores-Poole</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Angus</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Coull</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Davy</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gilmour-Graham</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mcilroy</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kendall</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pal</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Messeder</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Thomson</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Johnston</surname><given-names>V.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Raby</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kinnear</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>P. F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wishart</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Grosset</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Burns</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cunnington</surname><given-names>A. L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Newman</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Vennard</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dalton</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Murphy</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ralph</surname><given-names>G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ritchie</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nelson</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>McEntee</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fowley</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hare</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Beaton</surname><given-names>G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wilson</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>McDonald</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Finlayson</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Donaldson</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sutherland</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bramley</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dunn</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wallis</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hewitt</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Morgan</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Falconer</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Peacock</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>McAlpine</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>McBrearty</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lowe</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Findlay</surname><given-names>N.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Adam</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tearney</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Picken</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>MacKenzie</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>McCallum</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sidney</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Downie</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Donnelly</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>McAllister</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Campbell</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Maclachlan</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Shearer</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Campbell</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Duncan</surname><given-names>G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Marrinan</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dewar</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kerr</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Killin</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Peters</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Stewart</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Daniels</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Darbyshire</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>McCoy</surname><given-names>I.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Duff</surname><given-names>U.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Young</surname><given-names>F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Orr</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Telford</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fraser</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Borthwick</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bailey</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Karbownicki</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>McLeod</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sutherland</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sammler</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Whyte</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Young</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gillies</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gall</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dallas</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cassidy</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Letham</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Salisbury</surname><given-names>V.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Anderson</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hutton</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Waggett</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Anderson</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mcgee</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cooper</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mamutse</surname><given-names>G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Niruban</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bath</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wiltshire</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Harmer</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wright</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Graham</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Richardson</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tyler</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Isaacs</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Crow</surname><given-names>N.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pinnell</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Neale</surname><given-names>W.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Maloney</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Weller</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Young</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Squire</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Whone</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hernandez</surname><given-names>Y.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Findlay</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>King</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gethin</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ticehurst</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Swift</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Short</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dean</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Westcott</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cottrell</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kruszynska</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kamath</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Q.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hall</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wilson</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Goodhand</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mellows</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cottam</surname><given-names>L. J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Behan</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gibson</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lomas</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kirk</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Benson</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Raw</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mulligan</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ansari</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Irving</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Javed</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hussain</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Joseph</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Brooke</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Melville</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>McCormack</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Stockley</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ganderton</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cherriman</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Price</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Douglas</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cooter</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bushell</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sheridan</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Browning</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Polverino</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Malone</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jackson</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Foden</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>James</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hayes</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Roberts</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Davis</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Clarke</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nicholl</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Majeed</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Oo</surname><given-names>M. T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Blachford</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Boughey</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kaur</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kaur</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Awan</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rahman</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Round</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gandecha</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Williams</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dealing</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Moss</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Talbot</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cooper</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sophia</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Allen</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cox</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Moreira</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Woolven</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sharratt</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Foster</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hurren</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Watson</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Northover</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Green</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Treloggen</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pawley</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Beesley</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Milne</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Howard</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Craw</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lewis</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Whitcher</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Vickers</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Russell</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sykes</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Meikle</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Loraine</surname><given-names>N.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Steiger</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Treloar</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Roebuck</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nashed</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Garfield-Smith</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mills</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Griffin</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Marshall</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>De Selincourt</surname><given-names>G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Queen</surname><given-names>V.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Stone</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Farrow-Jones</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sturdy</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Almedilla</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fitzsimmons</surname><given-names>F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Alison</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rogers</surname><given-names>F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Reed</surname><given-names>B.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pinkney</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Muzerengi</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Stafford</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Parmar</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Albutt</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kaur</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Awan</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rahman</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Leahy</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Allain</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sritharan</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Daniell</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kunsteinaite</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Slade</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pimbblet</surname><given-names>F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Killourhey</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wales</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hughes</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Horsfield</surname><given-names>G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mercer</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Roberts</surname><given-names>Z.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Stock</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Evans</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Boyd</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>King</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Birch</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Anderson</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Evans</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Stapleton</surname><given-names>N.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Magennis</surname><given-names>U.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Vernall</surname><given-names>R.</given-names></name></contrib></contrib-group></collab>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.13097.3c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2322 6764</institution-id><institution>Population Health Sciences, </institution><institution>Addison House, Kingâ€™s College London, </institution></institution-wrap>Guyâ€™s Campus, London, SE1 1UL UK </aff>
                <aff id="Aff2"><label>2</label>School of Health Science, University of Nottingham, QMC, Nottingham, NG7 2HA UK </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.4563.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8868</institution-id><institution>Nottingham Clinical Trials Unit, </institution><institution>University of Nottingham, </institution></institution-wrap>Building 42, University Park, Nottingham, NG7 2RD UK </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.6572.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7486</institution-id><institution>Birmingham Clinical Trials Unit, </institution><institution>University of Birmingham, </institution></institution-wrap>Birmingham, B15 2TT UK </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.5214.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 0669 8188</institution-id><institution>NMAHP Research Unit, Glasgow Caledonian University, </institution></institution-wrap>Glasgow, G4 0BA UK </aff>
                <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.413301.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 0523 9342</institution-id><institution>Queen Elizabeth Hospital, NHS Greater Glasgow and Clyde, </institution></institution-wrap>Glasgow, UK </aff>
                <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.127050.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 0249 951X</institution-id><institution>School of Allied and Public Health Professions, Canterbury Christ church University, </institution></institution-wrap>Canterbury, CT1 1QU UK </aff>
                <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.7362.0</institution-id><institution-id institution-id-type="ISNI">0000000118820937</institution-id><institution>Bangor Institute for Health and Medical Research, School of Healthcare Sciences, Bangor University, </institution></institution-wrap>Bangor, UK </aff>
                <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.24029.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0383 8386</institution-id><institution>Cambridge Clinical Trials Unit, </institution><institution>Cambridge University Hospitals NHS Foundation Trust, </institution></institution-wrap>Cambridge, CB2 0QQ UK </aff>
                <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.6572.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7486</institution-id><institution>Health Economics, University of Birmingham, </institution></institution-wrap>Birmingham,, B15 2TT UK </aff>
                <aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution>Division of Psychology and Language Science, Faculty of Brain Sciences, </institution><institution>University College London, </institution></institution-wrap>London, UK </aff>
                <aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="GRID">grid.6572.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7486</institution-id><institution>Institute for Applied Health Research, University of Birmingham, </institution></institution-wrap>Birmingham, B15 2TT UK </aff>
                <aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.412919.6</institution-id><institution>Department of Neurology, </institution><institution>Sandwell and West Birmingham Hospitals NHS Trust, </institution></institution-wrap>Birmingham,, B18 7QH UK </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>27</day>
                <month>5</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>27</day>
                <month>5</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2020</year>
              </pub-date>
              <volume>21</volume>
              <elocation-id>436</elocation-id>
              <history>
                <date date-type="received">
                  <day>19</day>
                  <month>2</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>27</day>
                  <month>4</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Â© The Author(s) 2020</copyright-statement>
                <license license-type="OpenAccess">
                  <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Background</title>
                  <p id="Par1">Parkinsonâ€™s disease (PD) affects approximately 145,519 people in the UK. Speech impairments are common with a reported prevalence of 68%, which increase physical and mental demands during conversation, reliance on family and/or carers, and the likelihood of social withdrawal reducing quality of life. In the UK, two approaches to Speech and Language Therapy (SLT) intervention are commonly available: National Health Service (NHS) SLT or Lee Silverman Voice Treatment (LSVT LOUDÂ®). NHS SLT is tailored to the individualsâ€™ needs per local practice typically consisting of six to eight weekly sessions; LSVT LOUDÂ® comprises 16 sessions of individual treatment with home-based practice over 4â€‰weeks. The evidence-base for their effectiveness is inconclusive.</p>
                </sec>
                <sec>
                  <title>Methods/design</title>
                  <p id="Par2">PD COMM is a phase III, multicentre, three-arm, unblinded, randomised controlled trial. Five hundred and forty-six people with idiopathic PD, reporting speech or voice problems will be enrolled. We will exclude those with a diagnosis of dementia, laryngeal pathology or those who have received SLT for speech problems in the previous 2â€‰years. Following informed consent and completion of baseline assessments, participants will be randomised in a 1:1:1 ratio to no-intervention control, NHS SLT or LSVT LOUDÂ® via a central computer-generated programme, using a minimisation procedure with a random element, to ensure allocation concealment. Participants randomised to the intervention groups will start treatment within 4 (NHS SLT) or 7 (LSVT LOUDÂ®) weeks of randomisation.</p>
                  <p id="Par3">Primary outcome: Voice Handicap Index (VHI) total score at 3â€‰months. Secondary outcomes include: VHI subscales, Parkinsonâ€™s Disease Questionnaire-39; Questionnaire on Acquired Speech Disorders; EuroQol-5D-5â€‰L; ICECAP-O; resource utilisation; adverse events and carer quality of life. Mixed-methods process and health economic evaluations will take place alongside the trial. Assessments will be completed before randomisation and at 3, 6 and 12â€‰months after randomisation.</p>
                  <p id="Par4">The trial started in December 2015 and will run for 77â€‰months. Recruitment will take place in approximately 42 sites around the UK.</p>
                </sec>
                <sec>
                  <title>Discussion</title>
                  <p id="Par5">The trial will test the hypothesis that SLT is effective for the treatment of speech or voice problems in people with PD compared to no SLT. It will further test whether NHS SLT or LSVT LOUDÂ® provide greater benefit and determine the cost-effectiveness of both interventions.</p>
                </sec>
                <sec>
                  <title>Trial registration</title>
                  <p id="Par6">International Standard Randomised Controlled Trials Number (ISRCTN) Registry, <ext-link ext-link-type="uri" xlink:href="http://www.isrctn.com/ISRCTN12421382">ID: 12421382</ext-link>. Registered on 18 April 2016.Â </p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Idiopathic Parkinsonâ€™s disease</kwd>
                <kwd>Lee Silverman voice treatment</kwd>
                <kwd>Speech and language therapy</kwd>
                <kwd>Randomised controlled trial</kwd>
                <kwd>Dysarthria</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000664</institution-id>
                      <institution>Health Technology Assessment Programme</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>10/135/02</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>Â© The Author(s) 2020</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Background</title>
              <p id="Par25">In prevalence and years lived with disability, Parkinsonâ€™s disease (PD) is the fastest-growing neurological disorder in the world [<xref ref-type="bibr" rid="CR1">1</xref>], and it affects approximately 145,519 people in the UK. PD is a complex, progressive condition with a range of motor and non-motor symptoms [<xref ref-type="bibr" rid="CR2">2</xref>]. Speech impairments are common in the PD population with a reported prevalence of 68% for patient-perceived problems and 71% for listener-rated speech impairment [<xref ref-type="bibr" rid="CR3">3</xref>]. In a study of 125 participants with PD [<xref ref-type="bibr" rid="CR4">4</xref>], 38% placed speech among their top four concerns and, in another study, 29% of participants [<xref ref-type="bibr" rid="CR5">5</xref>] reported speech problems to be among their greatest present difficulties. Miller et al. [<xref ref-type="bibr" rid="CR6">6</xref>] noted how changes in communication led to increased physical and mental demands during conversation, an increased reliance on family members and/or carers, and an increased likelihood of social withdrawal. The speech of people with PD is often perceived as sounding quiet and imprecise, creating a potential social barrier to communication [<xref ref-type="bibr" rid="CR7">7</xref>]. A qualitative study involving 24 people living with PD identified problems with speaking as an activity. The interviewees reported having to think more about speaking; weighing up the value versus the effort of speaking; having negative feelings about speaking; finding that speaking is influenced by different people and places; and having to adjust to the effect of speaking of the disease progression and their medication [<xref ref-type="bibr" rid="CR8">8</xref>]. Overall, impairments of speech have been recognised to reduce the quality of life of people with PD [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p>
              <p id="Par26">Speech and Language Therapy (SLT) for speech difficulties in people with PD in the UK aims to improve communication. Some therapy approaches engage the person with PD in exercises to improve motor skills, others support the communication partnership between the person with PD and their communication partner, while others consider augmentation, or alternative means of communication. Following assessment and discussion with the person with PD, an individually tailored therapy plan is developed to address their needs and those of their family. For the purposes of the PD COMM trial, any of the above will be included in the intervention arm called â€˜standard National Health Service (NHS) SLTâ€™. This â€˜standard NHS SLTâ€™ is distinct from the other trial intervention arm which comprises Lee Silverman Voice Treatment (LSVT LOUDÂ®) [<xref ref-type="bibr" rid="CR11">11</xref>]. Within the PD COMM trial two types of SLT will be assessed: standard NHS SLT and LSVT LOUDÂ® [<xref ref-type="bibr" rid="CR11">11</xref>] against a no-SLT control.</p>
              <p id="Par27">Standard NHS SLT can include any of the above with the therapist selecting from multifaceted therapy components and tailoring these to the needs of the individual, their impairment and participation targets and within the constraints for that particular clinical service [<xref ref-type="bibr" rid="CR6">6</xref>]. Typically, weekly sessions over 6â€“8â€‰weeks are prescribed, either individually or in groups [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. LSVT LOUDÂ® differs from standard NHS SLT in that it is a more prescriptive therapy. The focus of LSVTÂ® is to â€˜think loudâ€™; improving phonation and vocal loudness through better vocal fold adduction [<xref ref-type="bibr" rid="CR14">14</xref>] over an intervention lasting for 16 sessions. The single focus and intensive delivery is used to â€˜recalibrateâ€™ the patient, so that they recognise that a voice which sounds too loud to them is necessary for them to be understood by other people. LSVT LOUDÂ® is increasingly being used in the NHS, but in the context of PD COMM, standard NHS SLT excludes the delivery of LSVTÂ®.</p>
              <p id="Par28">A Cochrane review of SLT versus no intervention (last search date 11 April 2011) identified three randomised controlled trials (RCTs) of differing SLT interventions versus no intervention (<italic>n</italic>â€‰=â€‰63) [<xref ref-type="bibr" rid="CR15">15</xref>]. The SLT evaluated varied from: 10â€‰h over 4â€‰weeks of individual therapy focussing on prosodic features of pitch and volume reinforced by visual feedback [<xref ref-type="bibr" rid="CR16">16</xref>]; 16â€‰h over 4â€‰weeks of LSVT [<xref ref-type="bibr" rid="CR11">11</xref>]; and 35â€“40â€‰h over 2â€‰weeks improving loudness and pitch variation, respiration, voice production and intelligibility reinforced by visual feedback primarily in a group setting [<xref ref-type="bibr" rid="CR17">17</xref>]. The review authors concluded that while outcome measures improved following SLT, the small participant numbers, low RCT quality and the possibility of publication bias, meant that the efficacy of SLT for progressive dysarthria in PD against a placebo or no intervention could not be confirmed or refuted. In another Cochrane review of six trials comparing different theoretical approaches to SLT provision for people with dysarthria (<italic>n</italic>â€‰=â€‰159) [<xref ref-type="bibr" rid="CR18">18</xref>]. All six trials assessed intelligibility and almost all of the results were not statistically significant. The exception to this was for one of the three types of perceptual ratings of speech recordings made in the study by Halpern et al. [<xref ref-type="bibr" rid="CR19">19</xref>] for which LSVT gave the greater improvement (<italic>n</italic>â€‰=â€‰14). Herd et al. [<xref ref-type="bibr" rid="CR18">18</xref>] concluded that the small number of participants examined, the low methodological quality of the trials evaluated, and the possibility of publication bias resulted in an inability to determine the superiority of any one type of SLT over another. Since these reviews were published, two further RCTs have been reported: the PD COMM Pilot trial [<xref ref-type="bibr" rid="CR13">13</xref>] (described below) and a trial comparing LSVT LOUDÂ® with LSVT ARTICÂ® (a second type of LSVT focussing on increased movement amplitude directed predominately to the orofacial-articulatory system, but with the same dosing schedule and intensity) with a no SLT intervention control in people with PD and healthy controls [<xref ref-type="bibr" rid="CR20">20</xref>]. The latter trial included 64 people with PD and measured sound pressure level (SPL) differences and a modified Communications Effectiveness Index (CETI-M) at 1 and 7â€‰months. LSVT LOUDÂ® significantly increased SPL at 1 and 7â€‰months compared to LSVT ARTICÂ® and control. Both LSVT groups also showed a greater improvement than control in CETI-M at 1â€‰month, but this difference was not maintained at 7â€‰months. A pilot trial (PD COMM Pilot) randomised 89 people with speech problems into a three-arm, assessor-blinded RCT to assess the feasibility and to inform the trial design of a full-scale RCT [<xref ref-type="bibr" rid="CR15">15</xref>]. Participants were randomised to either LSVT LOUDÂ®, standard NHS SLT or no intervention control in a 1:1:1 ratio. The pilot trial showed a trend towards improvement in the LSVT LOUDÂ® and SLT groups over the control group at 3â€‰months, but the findings were not powered to give a definitive answer.</p>
              <p id="Par29">The PD COMM trial design was informed by our PD COMM Pilot trial, which was funded by The Dunhill Medical Trust. The PD COMM trial is funded by the UK National Institute for Health Research Health Technology Assessment programme (10/135/02). Further support was provided by Professor Lori Ramig in the form of free LSVT LOUDÂ® training. The protocol is reported using the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) [<xref ref-type="bibr" rid="CR21">21</xref>] and Template for Intervention Description and Replication (TIDieR) [<xref ref-type="bibr" rid="CR22">22</xref>] guidelines.</p>
            </sec>
            <sec id="Sec2">
              <title>Methods/design</title>
              <p id="Par30">The PD COMM trial protocol can be found on: <ext-link ext-link-type="uri" xlink:href="https://www.birmingham.ac.uk/research/activity/mds/trials/bctu/trials/pd/PD-COMM/investigators/documentation.aspx">https://www.birmingham.ac.uk/research/activity/mds/trials/bctu/trials/pd/PD-COMM/investigators/documentation.aspx</ext-link> (last accessed 10 September 2019). The trial received ethical approval on 7 December 2015 by the West Midlands NHS Research Ethics Committee (REC) (15/WM/0443), with protocol version 4.0 (14 November 2018) currently in effect (see the â€˜Protocol amendmentsâ€™ section below for details). The project is sponsored by the University of Birmingham (Research Governance Team, University of Birmingham, Birmingham, B15 2TT).</p>
              <p id="Par31">PD COMM is a multicentre, phase III, three-arm, unblinded RCT where participants are randomised in a 1:1:1 ratio to a no-intervention control group, NHS SLT or LSVT LOUDÂ®.</p>
              <p id="Par32">The primary objective of the trial is to evaluate the clinical and cost-effectiveness of the two types of SLT versus no SLT treatment (no SLT control) for people with PD, but the trial will also compare the two types of SLT (LSVT LOUDÂ® versus standard NHS SLT). Therefore, there will be three comparisons within the trial:
<list list-type="order"><list-item><p id="Par33">LSVT LOUDÂ® versus no SLT control</p></list-item><list-item><p id="Par34">Standard NHS SLT versus no SLT control</p></list-item><list-item><p id="Par35">LSVT LOUDÂ® versus standard NHS SLT</p></list-item></list></p>
              <p id="Par36">Patient-reported measures are being used to assess the participantâ€™s perception of how their voice impacts on daily activities and their quality of life to assess clinical effectiveness. The quality of life of carers will also be assessed, and a cost-effectiveness analysis will be performed.</p>
              <sec id="Sec3">
                <title>Participant characteristics</title>
                <p id="Par37">People will be eligible for recruitment into the trial if they have idiopathic PD as defined by the 1988 UK PDS Brain Bank Criteria [<xref ref-type="bibr" rid="CR23">23</xref>]; they, or their carer, report problems with speech or voice when asked and they have no signs of dementia â€“ typically this is determined by the person with a PD clinician as per local practice. Furthermore, they must not have evidence of laryngeal pathology including: vocal nodules, a history of vocal strain or previous laryngeal surgery as such patients may not be suitable for LSVT LOUDÂ®; and have not received SLT for speech- or voice-related problems in the past 2â€‰years, as there is some evidence that benefits of LSVT may persist for 24â€‰months [<xref ref-type="bibr" rid="CR14">14</xref>].</p>
              </sec>
              <sec id="Sec4">
                <title>Identification, recruitment and randomisation</title>
                <p id="Par38">The trial is designed to align with routine care, thus minimising the burden for people with movement difficulties. Participants will usually be identified during routine clinic appointments with their clinician or Parkinsonâ€™s specialist nurse who will inform potentially eligible patients of the trial and provide a copy of the participant information sheet (PIS). The patient will be given time to review the PIS and/or go through it with a member of the team, typically the research nurse, and will be given the opportunity to ask questions. Given the low-risk nature of the trial, and the mobility limitations of the population, participants may join the trial on the same day that they discuss the trial and receive the PIS or may come back at a later date if they prefer.</p>
                <p id="Par39">Following informed consent and completion of the baseline assessment and questionnaires, the participant can be randomised into the trial. Prior to randomisation, the team will check the availability of speech and language therapists at that site. Randomisation may be deferred if the SLT intervention cannot be initiated within the set time frames â€“ however, the participantâ€™s baseline questionnaire needs to be completed within 2â€‰weeks prior to randomisation, so this should be factored in to any planned delay of a patientâ€™s randomisation. Typically the research nurse, will obtain informed consent and randomise the patient into the trial and liaise with the speech and language therapist to ensure that SLT (should they be randomised to therapy) starts within the required time frame.</p>
                <p id="Par40">Following informed consent and completion of all baseline data collection, participants will be randomised at the level of the individual via a central secure web-based randomisation system at the Birmingham Clinical Trials Unit (BCTU) to ensure concealment of the next treatment allocation. Typically, randomisation will be performed by the research nurse. The randomisation process will use a minimisation procedure with a random element. The following minimisation variables will be used:
<list list-type="bullet"><list-item><p id="Par41">Age (â‰¤â€‰59, 60â€“70, &gt;â€‰70â€‰years)</p></list-item><list-item><p id="Par42">Disease severity measured using the Hoehn and Yahr [<xref ref-type="bibr" rid="CR24">24</xref>] staging (1.0â€“2.5, 3.0â€“5.0) and</p></list-item><list-item><p id="Par43">Severity of speech measured using the Voice Handicap Index (VHI) [<xref ref-type="bibr" rid="CR25">25</xref>] total score (â‰¤â€‰33, mild 34â€“44, moderate 45â€“61, severe &gt;â€‰61)</p></list-item></list></p>
                <p id="Par44">Once randomised into the trial, NHS SLT should start within 4â€‰weeks and LSVT LOUDÂ® should start within 7â€‰weeks to enable the intervention to be completed prior to the primary end point (at 3â€‰months post randomisation). The trial will last for 77â€‰months. Recruitment will take place in approximately 42 sites around the UK (see TableÂ <xref rid="Tab1" ref-type="table">1</xref>).
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Participating sites and principal investigators (PIs)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Trust</th><th>PI</th></tr></thead><tbody><tr><td>Aneurin Bevan University Health Board</td><td>Alistair Church</td></tr><tr><td>Basildon and Thurrock University Hospitals NHS Foundation Trust</td><td>Sigurlaud Sveinbjornsdottir</td></tr><tr><td>Betsi Cadwaladr University Health Board</td><td>Sam Abraham</td></tr><tr><td>Blackpool Teaching Hospitals NHS Foundation Trust</td><td>David McGhee</td></tr><tr><td>Brighton and Sussex University Hospitals NHS Trust</td><td>Romi Saha</td></tr><tr><td>Cardiff and Vale University Health Board</td><td>Chris Thomas</td></tr><tr><td>Central London Community Healthcare NHS Trust</td><td>Ayano Funaki</td></tr><tr><td>East Cheshire NHS Trust</td><td>Monty Silverdale</td></tr><tr><td>Gloucestershire Hospitals NHS Foundation Trust</td><td>Sangeeta Kulkarni</td></tr><tr><td>Great Western Hospitals NHS Foundation Trust</td><td>Graham Lennox</td></tr><tr><td>Guyâ€™s and St Thomasâ€™ NHS Foundation Trust</td><td>Thomasin Andrews</td></tr><tr><td>Harrogate and District NHS Foundation Trust</td><td>Rosaria Buccoliero</td></tr><tr><td>Heart of England NHS Foundation Trust (now University Hospitals Birmingham NHS Foundation Trust)</td><td>Martha Pinkney</td></tr><tr><td>Homerton University Hospital NHS Foundation Trust</td><td>Laetitia Sautin</td></tr><tr><td>Hywel Dda University Health Board</td><td>Christopher James</td></tr><tr><td>Lancashire Teaching Hospitals NHS Trust</td><td>Tahir Majeed</td></tr><tr><td>Leeds Teaching Hospitals NHS Trust</td><td>Ioannis Mavroudis</td></tr><tr><td>London North West Healthcare NHS Trust</td><td>Judy Anne Juada</td></tr><tr><td>NHS Ayrshire and Arran</td><td>Andrew Watt</td></tr><tr><td>NHS Dumfries and Galloway</td><td>Shona Donaldson</td></tr><tr><td>NHS Forth Valley</td><td>Suvankar Pal</td></tr><tr><td>NHS Greater Glasgow and Clyde</td><td>Steven Wishart</td></tr><tr><td>NHS Highland/Argyll and Bute</td><td>Martin Wilson</td></tr><tr><td>NHS Lanarkshire</td><td>Helen Morgan</td></tr><tr><td>NHS Lothian</td><td>Gordon Duncan</td></tr><tr><td>NHS Tayside</td><td>Derek Sutherland</td></tr><tr><td>Norfolk and Norwich University Hospitals NHS Trust</td><td>Stephanie Cooper</td></tr><tr><td>Norfolk Community Health and Care NHS Trust</td><td>Lauren Issacs</td></tr><tr><td>North Bristol NHS Trust</td><td>Alan Whone</td></tr><tr><td>Northern Lincolnshire and Goole NHS Foundation Trust</td><td>Shankar Kamath</td></tr><tr><td>Pennine Acute Hospitals NHS Trust</td><td>Jason Raw</td></tr><tr><td>Powys Teaching UHB</td><td>Jane Price</td></tr><tr><td>Royal Devon and Exeter NHS Foundation Trust</td><td>Ray Sheridan</td></tr><tr><td>Sandwell and West Birmingham Hospitals NHS Trust</td><td>Carl Clarke</td></tr><tr><td>St Helens and Knowsley Hospitals NHS Trust</td><td>Dipen Gandecha</td></tr><tr><td>Taunton and Somerset NHS Foundation Trust</td><td>Simon Cooper</td></tr><tr><td>The Walton Centre NHS Foundation Trust</td><td>Malcolm Steiger</td></tr><tr><td>Torbay and South Devon NHS Foundation Trust</td><td>Rachel Nashed</td></tr><tr><td>University Hospitals Bristol NHS Foundation Trust</td><td>Theresa Allain</td></tr><tr><td>University Hospitals of South Manchester NHS Foundation Trust (now Manchester University NHS Foundation Trust)</td><td>David Ahearn</td></tr><tr><td>Bath and North East Somerset Community Health and Care Services NHS</td><td>Veronica Lyell</td></tr><tr><td>Wye Valley NHS Trust</td><td>Emma Wales</td></tr></tbody></table></table-wrap></p>
                <sec id="Sec5">
                  <title>Interventions</title>
                  <sec id="FPar1">
                    <title>Standard NHS SLT</title>
                    <p id="Par45">Standard NHS SLT is not prescriptive and does not have standard content or dosage. It is, therefore, not possible to predict the number of sessions that will be provided. A survey of current UK SLT practice for PD [<xref ref-type="bibr" rid="CR12">12</xref>] reported a median dose of six sessions delivered over 42â€‰days. The PD COMM Pilot trial found the median dose to be six sessions (range 1â€“14) over an average of 9.6â€‰weeks (standard deviation 6.1â€‰weeks) [<xref ref-type="bibr" rid="CR13">13</xref>].</p>
                    <p id="Par46">Treatment is typically tailored to the individualâ€™s level of difficulty or dysarthria severity and their interests as individual need and clinical constraints. Treatment will be individualised to suit each participantâ€™s needs as per local practice. It may include impairment-based interventions, compensatory interventions and augmentative and alternative communication (ACC) strategies aimed at improving communication and participation. The participantâ€™s family/carer(s) may be involved. Therefore, the NHS SLT arm will encompass any SLT interventions that are not LSVT LOUDÂ® as per the LSVT LOUDÂ® protocol.</p>
                    <p id="Par47">Treatments targeted at impairment level may include exercises focussed on improving capacity, control and co-ordination of respiration, techniques for improving phonation intensity and co-ordination with respiration (but not LSVT LOUDÂ®), and exercises to improve the range, strength and speed of the articulatory muscles [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Behavioural therapy may include interventions aimed at reducing prosodic abnormality [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>] such as exercises targeting pitch, intonation, stress patterns and volume variation [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR26">26</xref>â€“<xref ref-type="bibr" rid="CR28">28</xref>], and techniques to address the overall rate of speech [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>] including the use of therapeutic devices such as pacing boards [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. AAC strategies such as topic and alphabet supplementation through communication books and boards may be employed [<xref ref-type="bibr" rid="CR31">31</xref>] along with AAC devices such as voice amplifiers, delayed auditory feedback systems and masking devices [<xref ref-type="bibr" rid="CR32">32</xref>â€“<xref ref-type="bibr" rid="CR34">34</xref>]. The practice of pitch-limiting voice treatment [<xref ref-type="bibr" rid="CR35">35</xref>] may also be utilised within the standard SLT intervention.</p>
                    <p id="Par48">The above methods may include techniques used in LSVT LOUDÂ®, e.g. vocal intensity exercises, but will be distinct by the individualised treatment, other SLT strategies, lower intensity of delivery and (potentially) the use of group intervention.</p>
                    <p id="Par49">Dose will be determined by the therapist reflecting participantsâ€™ individual needs, but the duration is unlikely to exceed 12 weeks of treatment. Sessions will be conducted by a suitably trained speech and language therapist or therapy assistant on a one-to-one or group basis per participant need and local practice. Sessions may take place in out-patient clinics, the participantâ€™s home or in the community.</p>
                  </sec>
                  <sec id="FPar2">
                    <title>LSVT LOUDÂ®</title>
                    <p id="Par50">The LSVT LOUDÂ® intervention is prescriptive and consists of four 50-min sessions per week delivered over 4 weeks [<xref ref-type="bibr" rid="CR36">36</xref>]. Each session follows a similar structure: 25â€‰min of repeated and intensive maximum-effort drills, and 25â€‰min of high-effort speech production tasks [<xref ref-type="bibr" rid="CR36">36</xref>]. Participants will also be set 5 to 10â€‰min of home-based practice tasks on treatment days, and up to 30â€‰min of home-based practice tasks on non-treatment days [<xref ref-type="bibr" rid="CR37">37</xref>].</p>
                    <p id="Par51">Content will consist of repeated repetitions of sustained â€˜ahâ€™ phonation, maximum fundamental frequency-range high- and low-pitch glides, and functional sentence repetition for the first half of each session, and exercises using speech production hierarchy that progresses throughout duration of the treatment programme (single word, phrases, sentences, paragraph reading, conversation) during the second half of the sessions [<xref ref-type="bibr" rid="CR37">37</xref>]. Throughout all of the sessions, the focus of the intervention will be to â€˜think loudâ€™, maintaining the vocal loudness produced during vowel phonation throughout all other tasks during the treatment [<xref ref-type="bibr" rid="CR36">36</xref>].</p>
                    <p id="Par52">Sessions will be conducted by a suitably trained speech and language therapist or therapy assistant on a one-to-one basis. Sessions may take place in out-patient clinics, the participantâ€™s home or remotely using tele-LSVT software. Once the exercises have been established, LSVT LOUDÂ® may be delivered using the LSVT companion software for a proportion of the time, in line with local practice.</p>
                  </sec>
                  <sec id="FPar3">
                    <title>Control</title>
                    <p id="Par53">The control group will not receive any SLT for their speech for 12â€‰months, unless it becomes clinically necessary. At the end of 12â€‰months, participants will be treated per local practice. If the participant needs SLT prior to 12â€‰months, with their continued consent, they will remain in the trial and be followed up as usual and included in the trial analyses.</p>
                    <p id="Par54">Participants are free to withdraw from the trial at any time or they may agree to continue in the trial but not comply with treatment. In the latter case they will continue to be followed up as per the protocol and the data will be analysed according to the group that they were randomised to (intention to treat).</p>
                  </sec>
                </sec>
                <sec id="Sec6">
                  <title>Outcomes</title>
                  <p id="Par55">Following the analysis of PD COMM Pilot, the design of the trial was refined to reduce the burden on participants and speech and language therapists by excluding the battery of vocal assessments and the Voice-related Quality of Life [<xref ref-type="bibr" rid="CR38">38</xref>] questionnaire.</p>
                </sec>
              </sec>
              <sec id="Sec7">
                <title>Primary outcome</title>
                <p id="Par56">The primary outcome measure for the trial is patient reported Voice Handicap Index (VHI) [<xref ref-type="bibr" rid="CR25">25</xref>] total score at 3â€‰months.</p>
                <p id="Par57">There was some discussion about the choice of primary outcome, as most previous trials had used vocal loudness. The VHI was chosen given that it is patient-reported, brief, (and from the pilot trial) well-completed and, in our view, better reflects the focus of the trial. Alongside the VHI, a battery of patient-reported outcomes (PROs; see the â€˜Secondary outcomesâ€™ section) are being collected, which cover a range of other important areas. In the pilot trial, extensive vocal assessments were carried out alongside the PROs. We decided not to undertake vocal assessments within the PD COMM trial as (1). the additional time involved was prohibitive; (2). there was concern that since one of the trial interventions (LSVT LOUDÂ®) specifically focussed on vocal loudness that the results might be skewed in favour of this intervention and (3). the focus of the trial was on the participants self-perception of functional communication rather than vocal loudness.</p>
              </sec>
              <sec id="Sec8">
                <title>Secondary outcomes</title>
                <p id="Par58">Patient reported: Subscales of the VHI [<xref ref-type="bibr" rid="CR25">25</xref>]; Parkinsonâ€™s Disease Questionnaire-39 (PDQ-39) [<xref ref-type="bibr" rid="CR39">39</xref>]; Questionnaire on Acquired Speech Disorders (QASD) [<xref ref-type="bibr" rid="CR40">40</xref>]; EuroQol-5D (5-level version) [<xref ref-type="bibr" rid="CR41">41</xref>]; ICEpop Capabilities Measure for Older Adults (ICECAP-O) [<xref ref-type="bibr" rid="CR42">42</xref>]; resource utilisation; and adverse events (AEs).</p>
                <p id="Par59">Carer reported: Carer quality of life (Parkinsonâ€™s Disease Questionnaireâ€“Carers) [<xref ref-type="bibr" rid="CR43">43</xref>].</p>
              </sec>
              <sec id="Sec9">
                <title>Other data collected includes</title>
                <p id="Par60">Demographics including height (baseline only), weight and Hoehn and Yahr stage (at baseline and 12â€‰months) [<xref ref-type="bibr" rid="CR24">24</xref>]; PD medication; Abbreviated Mental Test [<xref ref-type="bibr" rid="CR44">44</xref>] (intervention arms only), therapy logs including home-based therapy diaries, NHS therapy notes and a global rating scale (Transition item).</p>
                <sec id="Sec10">
                  <title>Adverse events</title>
                  <p id="Par61">A risk assessment of the PD COMM trial has been performed with the SLT interventions considered to be of low risk. From the literature, the only reported AE associated with the interventions was a small increased risk of vocal strain or abuse; however, none were reported in the PD COMM Pilot trial. This risk will be minimised: speech and language therapists are trained to identify and rehabilitate vocal strain so, if present, the therapist will be able to identify and address it. No other risks are expected to arise from taking part in the trial. It is, therefore, reasonable to collect only targeted AEs.</p>
                  <p id="Par62">For participants in either therapy arm, any vocal strain or abuse believed to be associated with treatment will be identified by the therapists at the participantsâ€™ therapy session and will be reported in the AE log.</p>
                  <p id="Par63">In all trial arms, BCTU will also check the participant-reported resource usage form to ensure that no vocal strain or abuse has occurred following participants reporting out-patients appointments with ear, nose and throat (ENT) specialists. At the 12-month clinical visit, the medical professional will also check whether any AEs have occurred since entering the trial.</p>
                  <p id="Par64">Serious adverse events (SAEs) are events that cause death, are life-threatening, require or extend an existing hospitalisation, result in persistent or significant disability or incapacity; or, are otherwise considered medically significant by the investigator. SAEs that are not related to vocal strain or abuse are excluded from expedited notification during the course of the trial and will be collected in the resource usage and 12-month clinical case report form (CRF).</p>
                </sec>
                <sec id="Sec11">
                  <title>Data collection</title>
                  <p id="Par65">Data is collected in clinic at baseline and 12â€‰months post randomisation at usual clinic appointments, and patient-reported outcome data is also collected at 3, 6 and 12â€‰months post randomisation by postal questionnaires to the participant which are returned directly to BCTU. Participants who do not comply with their treatment allocation will be followed up as other participants unless they chose to withdraw from the trial. Data is reviewed on receipt, and return rates and completeness are closely monitored throughout the trial to ensure patient retention. The Trial Management Group review return and completeness rates and can determine whether to trigger further review or monitoring.</p>
                  <p id="Par66">FigureÂ <xref rid="Fig1" ref-type="fig">1</xref> provides a flowchart of the trial design and TableÂ <xref rid="Tab2" ref-type="table">2</xref> denotes the schedule of events. Data is sent to BCTU where they are securely held in restricted-access areas and entered onto a bespoke trial database. For participants randomised to the intervention arms, further data around the interventions including therapy logs and therapy notes is sent to BCTU (see below). Redacted therapy notes and anonymised data sets will be sent to researchers at Glasgow Caledonian University for the intervention description analysis. This data will be integrated with the process evaluation data collected and held at the University of Bangor.
<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow diagram of trial design</p></caption><graphic xlink:href="13063_2020_4354_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>Time and event schedule</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Measure</th><th rowspan="2">Enrolment</th><th colspan="4">Assessment time</th></tr><tr><th>Allocation tâ€‰=â€‰0</th><th>3â€‰months</th><th>6â€‰months</th><th>12â€‰months</th></tr></thead><tbody><tr><td colspan="6"><bold>Enrolment</bold></td></tr><tr><td>â€ƒInformed consent</td><td>âœ“</td><td/><td/><td/><td/></tr><tr><td>â€ƒEligibility</td><td>âœ“</td><td/><td/><td/><td/></tr><tr><td>â€ƒAllocation</td><td/><td>âœ“</td><td/><td/><td/></tr><tr><td colspan="6"><bold>Interventions</bold></td></tr><tr><td>â€ƒInitial interview log and treatment record form (all sessions)</td><td/><td/><td>âœ“<sup>a</sup></td><td/><td/></tr><tr><td>â€ƒHome-based therapy diary</td><td/><td/><td>âœ“<sup>b</sup></td><td/><td/></tr><tr><td colspan="6"><bold>Assessments</bold></td></tr><tr><td>â€ƒBaseline case report form</td><td/><td>âœ“</td><td/><td/><td/></tr><tr><td>â€ƒVHI; PDQ-39; QASD; EQ-5D-5â€‰L; ICECAP-O</td><td/><td>âœ“</td><td>âœ“</td><td>âœ“</td><td>âœ“</td></tr><tr><td>â€ƒResource Usage Questionnaire</td><td/><td/><td>âœ“</td><td>âœ“</td><td>âœ“</td></tr><tr><td>â€ƒGlobal rating score (Transition item)</td><td/><td/><td>âœ“</td><td/><td/></tr><tr><td>â€ƒPDQ-Carer</td><td/><td>âœ“</td><td>âœ“</td><td>âœ“</td><td>âœ“</td></tr><tr><td>â€ƒAdverse event log</td><td/><td/><td>âœ“<sup>c</sup></td><td/><td/></tr><tr><td>â€ƒ12-month case report form</td><td/><td/><td/><td/><td>âœ“</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Following each therapy session for participants in the two SLT treatment arms only</p><p><sup>b</sup>Completed at home by the participant as recommended in their SLT therapy session</p><p><sup>c</sup>Only required for participants randomised to a treatment arm</p><p>Key: <italic>EQ-5D</italic> EuroQol 5-dimension, 5-level questionnaire, <italic>ICECAP-O</italic> ICEpop Capabilities Measure for Older Adults, <italic>QASD</italic> Questionnaire on Acquired Speech Disorders, <italic>PDQ-39</italic> Parkinsonâ€™s Disease Questionnaire-39, <italic>SLT</italic> Speech and Language Therapy, <italic>VHI</italic> Voice Handicap Index</p></table-wrap-foot></table-wrap></p>
                </sec>
                <sec id="Sec12">
                  <title>Treatment dose and fidelity</title>
                  <p id="Par67">The speech and language therapists will complete an initial interview log including the Abbreviated Mental Test and intervention record forms at each treatment session for participants receiving SLT. Furthermore, in the LSVT LOUDÂ® arm and where prescribed in the NHS SLT arm, participants will complete home-based therapy diaries. Therapists will also complete standard NHS therapy notes; upon trial treatment completion, a pseudo-anonymised (i.e. participant is only identified by trial number) version of these will be sent to the research team.</p>
                </sec>
                <sec id="Sec13">
                  <title>Process evaluation</title>
                  <p id="Par68">In order to evaluate the implementation of PD COMM interventions, a process evaluation will be carried out alongside PD COMM. The process evaluation team led by Bangor University will employ a number of approaches to data collection, including:
<list list-type="bullet"><list-item><p id="Par69">Qualitative interviews with PD COMM participants</p></list-item><list-item><p id="Par70">Qualitative interviews with PD COMM therapists</p></list-item><list-item><p id="Par71">Critical incident reports</p></list-item><list-item><p id="Par72">Therapistâ€™s questionnaire</p></list-item></list></p>
                  <p id="Par73">A detailed protocol for these analyses including intervention description has been published [<xref ref-type="bibr" rid="CR45">45</xref>].</p>
                  <p id="Par74">The analysis of process evaluation data will focus on the practical implementation of the trial interventions, including how these were tailored to individual patient and other circumstances.</p>
                </sec>
                <sec id="Sec14">
                  <title>Sample size</title>
                  <p id="Par75">The primary outcome is the mean difference in the VHI total score at 3â€‰months across the three comparisons: LSVT LOUDÂ® versus control; standard NHS SLT versus control; and LSVT LOUDÂ® versus standard NHS SLT. Data from the PD COMM Pilot trial was used to inform the sample size calculations for this trial as the minimal clinically important difference (MCID) for the VHI has not been established in PD patients. In the PD COMM Pilot trial, a difference of around 10 points in VHI total score was observed at 3â€‰months between SLT and control for both types of SLT (standard NHS and LSVT LOUDÂ®) versus control comparisons. To detect a 10-point difference in VHI total score between arms at 3â€‰months (using a two-sided <italic>t</italic> test and the upper standard deviation of 26.27 obtained from the VHI baseline data from the pilot trial; effect size 0.38), with 80% power and <italic>Î±</italic>â€‰=â€‰0.01, we need 163 participants per arm. Allowing for 10% drop-out will require 182 participants per arm, so 546 participants in total.</p>
                </sec>
                <sec id="Sec15">
                  <title>Statistical analysis</title>
                  <p id="Par76">All primary analyses (for both the primary and secondary outcomes) will be by intention to treat. Participants will be analysed in the treatment group to which they were randomised, and all participants will be included whether or not they received the allocated treatment. This is to avoid any potential bias in the analysis. For all tests, summary statistics (e.g. mean differences) will be reported along with 95% confidence intervals and <italic>p</italic> values from two-sided tests. A <italic>p</italic> value of &lt;â€‰0.01 will be considered statistically significant, as per the sample size calculations to take into account the multiple treatment comparisons being undertaken.</p>
                  <p id="Par77">There will be no interim analyses.</p>
                  <p id="Par78">The analysis and interpretation of qualitative data, and its integration with quantitative data on intervention provision, will be performed between researchers at Bangor University (Professor Christopher Burton) and Glasgow Caledonian University (Professor Marian Brady), with input from University College London (Dr Christina Smith) and Kingâ€™s College London (Professor Catherine Sackley).</p>
                </sec>
              </sec>
              <sec id="Sec16">
                <title>Primary outcome analysis</title>
                <p id="Par79">The primary outcome measure is the VHI total score at 3â€‰months. A linear regression model will be used to estimate differences in the VHI total score at 3â€‰months between the two arms of interest, with the VHI baseline score and the minimisation variables age and severity of PD (Hoehn and Yahr) included in the model as covariates.</p>
              </sec>
              <sec id="Sec17">
                <title>Secondary outcome analyses</title>
                <p id="Par80">The majority of the secondary outcome measures (e.g. PDQ-39) are continuous measurements and will be analysed in a similar way to that described for the primary analysis: a linear regression analysis adjusting for relevant baseline score and all of the minimisation variables (baseline VHI, age and severity of PD). As per the primary outcome, the primary analysis for the secondary outcomes will be based on the 3-month data.</p>
                <p id="Par81">To assess whether any treatment effect is maintained, participant- and carer-completed questionnaires are also being collected at 6 and 12â€‰months post randomisation. Data collected at 6 and 12â€‰months will be analysed using the same methods as described above. Further analysis using a repeated measures model will also be performed using all data over the 3-, 6- and 12-month assessment points.</p>
                <p id="Par82">A global rating scale (Transition item) will be completed by the participant and carer separately at the 3-month time point. This data will be used to calculate an MCID for the VHI in this population.</p>
                <p id="Par83">Adverse events and safety data will be summarised descriptively by treatment arm, and the number of events and percentage of participants experiencing any AE reported. It is not expected that there will be many AEs as a result of the intervention, but the number of participants reporting an AE will be compared using a chi-squared test, with relative risks and 95% confidence intervals reported (if appropriate).</p>
              </sec>
              <sec id="Sec18">
                <title>Planned subgroup analyses</title>
                <p id="Par84">Subgroup analyses will be performed for the primary outcome to assess whether there are differences in treatment effect by the minimisation variables: age; baseline voice severity (as measured by VHI); and PD severity (as measured by Hoehn and Yahr). The trial is not powered to detect differences in treatment effect in these subgroups and, therefore, these analyses will be treated as purely hypothesis generating.</p>
                <sec id="Sec19">
                  <title>Health economics analysis</title>
                  <p id="Par85">The economic evaluation will estimate the cost-effectiveness of LSVT LOUDÂ® or standard NHS SLT compared to no SLT treatment (control) in PD. The base-case economic evaluation will be undertaken from the UK NHS and personal social services (PSS) perspective, with further analysis from a broader societal perspective, over 12â€‰monthsâ€™ follow-up.</p>
                  <p id="Par86">A cost-effectiveness analysis will use the primary outcome (VHI) to calculate the cost per unit improvement in VHI score, and a cost-utility analysis will use responses from the EQ-5D-5â€‰L to calculate cost per quality-adjusted life year (QALY) gained. Resource-use data will be collected on PD-related medication, primary care and secondary care healthcare utilisation, including the use of therapy services, and use of social services including formal care. Further information will be collected on time off work, participant out-of-pocket costs and costs incurred by informal carers, in order to inform analysis from a societal perspective. The cost of delivering the LSVT LOUDÂ® intervention and NHS SLT, including length and number of sessions and any training required will be determined within the trial. Data will be collected using a participant-completed resource utilisation questionnaire (at 3, 6 and 12â€‰months) and the therapist-completed initial interview logs and treatment record forms. Unit costs from routine sources will be applied to resource-use data [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. Health-related quality of life will be assessed using the EQ-5D-5â€‰L [<xref ref-type="bibr" rid="CR41">41</xref>] collected at baseline, 3, 6 and 12â€‰months. The crosswalk value set will be applied to patient responses to obtain utility scores, in line with current NICE recommendations and QALYs calculated using the â€˜area under the curveâ€™ approach. The ICECAP-O [<xref ref-type="bibr" rid="CR42">42</xref>] will also be used to capture changes in participantsâ€™ capabilities, allowing a broader assessment of benefits to patients.</p>
                  <p id="Par87">Incremental cost-effectiveness and cost-utility analyses will be undertaken to estimate the incremental cost per unit of outcome gained, adjusting for baseline covariates. Two sets of comparisons will be undertaken. In line with convention, strategies will be ordered from least to greatest cost, with each strategy compared against the next more costly strategy, and strategies which are dominated or extendedly dominated subsequently excluded. A separate analysis will also consider the three pair-wise comparisons as specified in the statistical analysis. Both deterministic and probability sensitivity analysis will be undertaken and cost-effectiveness acceptability curves will be produced to reflect the probability the intervention will be cost-effective at different willingness to pay thresholds, in terms of cost per unit of outcome gained.</p>
                </sec>
                <sec id="Sec20">
                  <title>Dissemination</title>
                  <p id="Par88">The trial results will be disseminated widely through scientific conferences and peer-reviewed publications. Collaborators will be informed of the trial results at a national trial results meeting and participants will be sent a newsletter thanking them for their support and informing them of the trial results. We will also use social media and work with the Universities media services, National Institute of Health Research (NIHR) Health Technology Assessment (NIHR HTA) dissemination services and the Parkinsonâ€™s UK charity to broaden our dissemination to key stake-holders and the wider community.</p>
                </sec>
                <sec id="Sec21">
                  <title>Roles and responsibilities</title>
                  <p id="Par89">The study design, collection, management, analysis and interpretation of the data, publishing the data is the responsibility of the chief investigator, and the Collaborative Group, the trial is managed by the BCTU, with additional support for Scottish sites being provided by Glasgow Caledonian University. The process evaluation is managed by the University of Bangor and the intervention description analysis is managed by Glasgow Caledonian University. The sponsor and funder do not have a role in the above activities.</p>
                  <p id="Par90">Oversight of the trial is performed by the Trial Management Group, an independent Data Monitoring Committee (DMC) and Trial Steering Committee (TSC). The DMC and TSC membership (see TableÂ <xref rid="Tab3" ref-type="table">3</xref>) was agreed with the funder; these committees meet at least annually to review the data and progress of the trial. Annual reports are submitted to the NHS REC and monthly updates against pre-determined milestones are sent to the funder.
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Trial Oversight Committees</p></caption><table frame="hsides" rules="groups"><tbody><tr><td><bold>Trial Management Group</bold></td><td><bold>Data Monitoring Committee</bold></td></tr><tr><td>Professor Catherine Sackley (chief investigator)</td><td rowspan="2">Dr Carl Counsell (chair), Consultant Neurologist, University of Aberdeen</td></tr><tr><td>Ms Pui Au</td></tr><tr><td>Ms Gillian Beeston</td><td rowspan="2">Dr Katherine Deane, Senior Lecturer, University of East Anglia</td></tr><tr><td>Professor Marian Brady</td></tr><tr><td>Professor Christopher Burton</td><td>Dr Louise Hiller, Statistician, University of Warwick</td></tr><tr><td>Ms Maria Caulfield</td><td/></tr><tr><td>Professor Carl E Clarke</td><td><bold>Trial Steering Committee</bold></td></tr><tr><td>Ms Sylvia Dickson</td><td rowspan="2">Dr Lisa Shaw (chair), Senior Research Associate, University of Newcastle upon Tyne</td></tr><tr><td>Dr Sue Jowett</td></tr><tr><td>Dr Patricia Masterson Algar</td><td rowspan="2">Mr Chris Jeffery, Patient and Public Involvement Representative</td></tr><tr><td>Dr Avril Nicoll</td></tr><tr><td>Mrs Smitaa Patel</td><td rowspan="2">Ms Michelle Collinson, Senior Medical Statistician, University of Leeds</td></tr><tr><td>Dr Cally Rick</td></tr><tr><td>Mrs Natalie Rowland</td><td rowspan="2">Dr Linsay Pennington, Senior Lecturer and Speech and Language Therapist, University of Newcastle upon Tyne</td></tr><tr><td>Dr Christina Smith</td></tr><tr><td>Ms Rebecca Woolley</td><td>Professor Catherine Sackley, Professor of Rehabilitation, Kingâ€™s College London</td></tr><tr><td><bold>Former members</bold></td><td rowspan="2">Dr Paul Worth, Consultant in Neurology, Cambridge University Hospitals NHS Foundation Trust</td></tr><tr><td>Mr Francis Dowling</td></tr><tr><td>Mr Max Hughes</td><td/></tr><tr><td/><td><bold>Former member:</bold></td></tr><tr><td/><td>Mr John Carrington, Patient and Public Involvement Representative</td></tr><tr><td/><td>Professor Adam Gordon, Professor in Medicine of Older People, University of Nottingham</td></tr><tr><td/><td>Dr Simon Horton, Lecturer and Speech and Language Therapist, University of East Anglia</td></tr></tbody></table></table-wrap></p>
                </sec>
              </sec>
            </sec>
            <sec id="Sec22">
              <title>Discussion</title>
              <p id="Par91">The PD COMM trial is already the largest trial of SLT in PD to date (as of 10 September 2019, 329 participants have been recruited). It will provide robust evidence as to the effectiveness and cost-effectiveness of two types of SLT for people with PD enabling them, their clinicians and NHS decisions-makers to make informed choices.</p>
              <p id="Par92">There will also be benefits beyond the immediate trial results: the group has developed a research network of speech and language therapists in 42 sites around the UK, participated, and provided training in, LSVT LOUDÂ® (courtesy of Dr Lori Ramig), trials, other aspects of PD and research into SLT and information on best practice. This project will lay the foundation for further trials in SLT and lower the barriers to future research. Furthermore, we will develop a clear understanding of the range of SLT practice around the UK for people with speech or voice problems as a consequence of PD, in terms of dosage, content and availability.</p>
            </sec>
            <sec id="Sec23">
              <title>Trial status</title>
              <p id="Par93">Protocol version number and date: version 4.0 (14 November 2018).</p>
              <p id="Par94">The first participant was recruited into the trial on 11 October 2016. Recruitment is ongoing with an expected recruitment end date of 30 November 2020.</p>
            </sec>
          </body>
          <back>
            <glossary>
              <title>Abbreviations</title>
              <def-list>
                <def-item>
                  <term>AE</term>
                  <def>
                    <p id="Par7">Adverse event</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ACC</term>
                  <def>
                    <p id="Par8">Augmentative and alternative communication</p>
                  </def>
                </def-item>
                <def-item>
                  <term>BCTU</term>
                  <def>
                    <p id="Par9">Birmingham Clinical Trials Unit</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ENT</term>
                  <def>
                    <p id="Par10">Ear, nose and throat</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ICECAP-O</term>
                  <def>
                    <p id="Par11">ICEpop Capabilities Measure for Older Adults</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ISRCTN</term>
                  <def>
                    <p id="Par12">International Standard Randomised Controlled Trials Number</p>
                  </def>
                </def-item>
                <def-item>
                  <term>LSVT LOUDÂ®</term>
                  <def>
                    <p id="Par13">Lee Silverman Voice Treatment</p>
                  </def>
                </def-item>
                <def-item>
                  <term>MCID</term>
                  <def>
                    <p id="Par14">Minimal clinically important difference</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CETI-M</term>
                  <def>
                    <p id="Par15">Modified Communications Effectiveness Index</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PD</term>
                  <def>
                    <p id="Par16">Parkinsonâ€™s disease</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PDQ-39</term>
                  <def>
                    <p id="Par17">Parkinsonâ€™s Disease Questionnaire-39</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PIS</term>
                  <def>
                    <p id="Par18">Patient information sheet</p>
                  </def>
                </def-item>
                <def-item>
                  <term>RCTs</term>
                  <def>
                    <p id="Par19">Randomised controlled trials</p>
                  </def>
                </def-item>
                <def-item>
                  <term>SAE</term>
                  <def>
                    <p id="Par20">Serious adverse event</p>
                  </def>
                </def-item>
                <def-item>
                  <term>SPL</term>
                  <def>
                    <p id="Par21">Sound pressure level</p>
                  </def>
                </def-item>
                <def-item>
                  <term>SLT</term>
                  <def>
                    <p id="Par22">Speech and Language Therapy</p>
                  </def>
                </def-item>
                <def-item>
                  <term>VRQOL</term>
                  <def>
                    <p id="Par23">Voice-related Quality of Life</p>
                  </def>
                </def-item>
                <def-item>
                  <term>VHI</term>
                  <def>
                    <p id="Par24">Voice Handicap Index</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <fn-group>
              <fn>
                <p>
                  <bold>Publisherâ€™s Note</bold>
                </p>
                <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
              <fn>
                <p>C. Sackley and C. Rick contributed equally to this work.</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgements</title>
              <p>
                <bold>The PD COMM Collaborative Group</bold>
              </p>
              <p>Participating centres and PD COMM Collaborative Group members (*indicates current principal investigator and <sup>#</sup>indicates former principal investigator at that centre)</p>
              <p>Aneurin Bevan University Health Board: A Church*, A Davey, C Gallagher, A Conroy, S Bailey, B Done, D Davies</p>
              <p>Basildon and Thurrock University Hospitals NHS Foundation Trust: S Sveinbjornsdottir*, M Kasti<sup>#</sup>, K Allen, J Colnet, J Riches, L Kittridge, L Morris, C Waszkiewicz</p>
              <p>Bath and North East Somerset Community Health and Care Services; V Lyell*, V Page, N Bassford, H Rayner, E Henderson</p>
              <p>Betsi Cadwaladr University Health Board: S Abraham*, JV Hindle<sup>#</sup>, S Jones, P Martin-Forbes, C Watkins, A Roberts, E Newcombe, L Bibby, L Matthews, J Roberts, S Thomas, H Hawthorne, K Clewley, S Lord, J Roberts, G Bretag, S Noble</p>
              <p>Blackpool Teaching Hospitals NHS Foundation Trust: D McGhee*, H Mcclure, A Ling Zhi Teo, R Wheeldon, C Wilkinson, M Oprea, G Van Duyvenvoorde, N Wilson, L Evans, R Belshaw, A Clarke, M Turner, C Thompson</p>
              <p>Brighton and Sussex University Hospitals NHS Trust: R Saha*, J Aram, D Mullan, J Newman, K Micabel, H Robinson, K Chick, J Gaylard, J Cochrane</p>
              <p>Cardiff and Vale University Health Board: E Christopher Thomas*, A Kissick, P Wright, B Mohamed, S Mahon, T Williams, S Appleton, N Elliott, L Evans, J Ridley</p>
              <p>Central London Community Healthcare NHS Trust: A Funaki*, P Daly, J Hackworth, K Timms, L Evison, A Bajracharya</p>
              <p>East Cheshire NHS Trust: M Silverdale*, K Andrews, A Davies, R Bedford, A Jones, D Mournfield, L Howieson, V Price, J Hunter, A Baggs, L Evans, R Norton, M Holland, K Pointon</p>
              <p>Gloucestershire Hospitals NHS Foundation Trust: S Kulkarni*, S Bobeldijk, S Beames, J Cavanagh, S Sudlow</p>
              <p>Great Western Hospitals NHS Foundation Trust: G Lennox*, R Whittaker, D Nelson, S Pegler, C Drayson, P Turner, J Stockwell</p>
              <p>Guyâ€™s and St Thomasâ€™ NHS Foundation Trust: T Andrews*, E White, E Turner, T Burnay, C Hickey, S Warner</p>
              <p>Harrogate and District NHS Foundation Trust: R Buccoliero*, C Isles, C Stemp, J Guy, C Bennett, S Smith, P Randall, L Ware, J Cann</p>
              <p>Homerton University Hospital NHS Foundation Trust: L Sautin*, S Grobler<sup>#</sup>, S Adjei<sup>#</sup>, A Hankin, D Ovayolu, M Dobbs, O Joyce, R Humphreys, A Jha, C Holbrook, K Rowsell, F Johnson, H Thornley, S Conway</p>
              <p>Hywel Dda University Health Board: C James*, S Murrow, M Hughes, K Pope, C MacPhee, E Williams, R Hughes, A Evans, A Richmond, K Pilborough, K Campbell, S Elizabeth Davies, A Taylor, S Thomas, D Asandei</p>
              <p>Lancashire Teaching Hospitals NHS Trust: T Majeed*, J Dawber, S Furey, A Oppetit, J Birt, M Hare, V Fleming, A Timoroksa, H Al-Nufoury, S Sharp, L Freimann</p>
              <p>Leeds Teaching Hospitals NHS Trust: I Mavroudis*, J Alty<sup>#</sup>, E Richfield, J Harrison, V Smith, T Joyce, J Bamford, S Jamieson, J Cosgrove, S Butterworth, E Sacre, L Makawa, P Duggan-Carter, C Arnold, K Brown, P Mpofu, C Joyce, S Henderson, C Wiseman, L Hyne, B Stevens, A Wood, D Holland, V Smith</p>
              <p>London North West Healthcare NHS Trust; J Juada*, S Molloy<sup>#</sup>, C Pavel, M Dhanarante, T Adedoyin, C Rowbottom, L Little, R Choudhury, L Prados, A Kelly, R Eggers, T Saifee, P Poku, L Niepage</p>
              <p>Manchester University NHS Foundation Trust: D Ahearn*, A Fountain, A Curran</p>
              <p>NHS Ayrshire and Arran: A Watt*, M Wilson, A Anderson, M Graham, J Taylor, P Hewat</p>
              <p>NHS Dumfries and Galloway: S Donaldson*, H Moores-Poole, C Angus, S Coull, R Davy, A Gilmour-Graham, T Mcilroy, A Kendall</p>
              <p>NHS Forth Valley: S Pal*, E Messeder, D Thomson, V Johnston, P Raby, S Kinnear, P Faunce Smith</p>
              <p>NHS Greater Glasgow and Clyde: S Wishart*, D Grosset, J Burns, A Louise Cunnington, E Newman, C Vennard, C Dalton, T Murphy, G Ralph, A Ritchie, C Nelson, A McEntee, P Fowley, H Hare, G Beaton</p>
              <p>NHS Highland: M Wilson*, D McDonald, J Finlayson, A Donaldson, S Sutherland, S Bramley, C Dunn, M Wallis, S Hewitt</p>
              <p>NHS Lanarkshire: H Morgan*, A Falconer<sup>#</sup>, L Peacock; A McAlpine; C McBrearty; A Lowe; N Findlay; A Adam; C Tearney; J Picken; K MacKenzie; L McCallum; L Smith; M Sidney; P Downie; L Donnelly; R McAllister; S Campbell; S Maclachlan; L Shearer; K Campbell</p>
              <p>NHS Lothian: G Duncan*, S Marrinan, M Dewar, J Kerr, L Killin, A Peters, A Stewart, T Daniels, A Darbyshire, I McCoy, U Duff, F Young, S Orr, C Telford, D Fraser, S Borthwick, H Bailey, L Karbownicki, E McLeod</p>
              <p>NHS Tayside: D Sutherland*, E Sammler, L Whyte, C Young, L Gillies, L Gall, J Dallas, L Cassidy, E Letham, V Salisbury, L Anderson, C Hutton, S Waggett, D Anderson, A Mcgee</p>
              <p>Norfolk and Norwich University Hospitals NHS Trust: S Cooper*, G Mamutse, A Niruban, A Bath, A Wiltshire, M Harmer, C Wright, J Graham, K Richardson, J Tyler</p>
              <p>Norfolk Community Health and Care NHS Trust: L Isaacs*, N Crow, S Pinnell, W Neale, L Maloney, R Weller, K Young, C Squire</p>
              <p>North Bristol NHS Trust: A Whone*, Y Hernandez, H Findlay, K King, L Gethin, S Ticehurst, A Swift, J Short, J Dean, C Westcott, K Thomas, S Cottrell, D Kruszynska</p>
              <p>Northern Lincolnshire and Goole NHS Foundation Trust: S Kamath*, Q Ma, J Hall, R Wilson, H Goodhand, K Mellows, L Jayne Cottam, T Behan, J Gibson, E Lomas, J Kirk, L Smith, J Benson</p>
              <p>Pennine Acute Hospitals NHS Trust: J Raw*, P Mulligan, A Ansari, R Irving, A Javed, S Hussain, L Johnson, R Joseph, J Brooke, J Melville, M McCormack, J Stockley, D Ganderton, A Cherriman</p>
              <p>Powys Teaching Health Board: J Price*, C Douglas, C Cooter, J Bushell</p>
              <p>Royal Devon and Exeter NHS Foundation Trust: R Sheridan*, C Browning, K Polverino, T Malone, S Jackson, A Foden, R James, S Hayes, L Roberts, E Davis</p>
              <p>Sandwell and West Birmingham Hospitals NHS Trust: C Clarke*, D Nicholl, A Majeed, MT Oo, K Blachford, A Boughey, J Kaur, S Kaur, M Awan, S Rahman, J Round</p>
              <p>St Helens And Knowsley Hospitals NHS Trust: D Gandecha*, S Williams, S Dealing, H Moss, L Talbot</p>
              <p>Taunton and Somerset NHS Foundation Trust: S Cooper*, R Sophia, J Allen, S Cox, C Moreira, D Woolven, D Sharratt, E Foster, H Hurren, J Watson, S Northover, D Green, A Treloggen, C Pawley, K Beesley, K Milne, L Howard, S Craw, A Lewis, A Whitcher, C Vickers, T Russell, A Sykes, H Meikle, N Loraine</p>
              <p>The Walton Centre NHS Foundation Trust: M Steiger*, H Treloar, L Roebuck, M Taylor</p>
              <p>Torbay and South Devon NHS Foundation Trust: R Nashed*, J Garfield-Smith, S Mills, H Griffin, C Marshall, G De Selincourt, V Queen, M Stone, M Farrow-Jones, E Sturdy, K Almedilla, F Fitzsimmons, M Alison, F Rogers, B Reed</p>
              <p>University Hospitals Birmingham NHS Foundation Trust: M Pinkney*, S Jones<sup>#</sup>, S Muzerengi, M Johnson, S Stafford, E Parmar, J Albutt, S Kaur, M Awan, S Rahman, K Leahy</p>
              <p>University Hospitals Bristol NHS Foundation Trust: T Allain*, M Sritharan<sup>#</sup>, A Daniell, K Kunsteinaite, S Slade, F Pimbblet, C Killourhey</p>
              <p>Wye Valley NHS Trust: E Wales*, C Hughes, G Horsfield, L Mercer, Z Roberts, K Stock, M Evans, S Boyd, L King, J Birch, S Anderson, C Evans, N Stapleton, U Magennis, R Vernall</p>
              <sec id="FPar4">
                <title>Protocol amendments</title>
                <p id="Par95">Original application: v1.0 Protocol and participant CRFs. The protocol was approved subjected to minor changes. Resubmitted to the REC and approved as v1.1, 7 December 2015.</p>
                <p id="Par96">Amendment 3: update to protocol 2.0, consent form, PIS and questionnaires.</p>
                <p id="Par97">Amendment 10: update to protocol 4.0, participant &amp; carer consent form, participant and carer information sheet and participant CRFs. Creation of letter to accompany PIS (if posting), patient leaflet and poster.</p>
              </sec>
            </ack>
            <notes notes-type="author-contribution">
              <title>Authorsâ€™ contributions</title>
              <p>Authors CS, MB, CB, CC, NI, CJ, SP, CR and CHS made substantial contributions to the conception and design of the trial. Authors PA, GB, MC, SD, FD, MH, PMA and AN, made substantial contributions to the acquisition of data. All authors are key to the management, and ongoing oversight of the trial. Author CR drafted the work and all authors read, edited and approved the final manuscript.</p>
            </notes>
            <notes notes-type="funding-information">
              <title>Funding Acknowledgement and Disclaimer</title>
              <p>This study is funded by the NIHR HTA programme (HTA: 10/135/02). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The study design, collection, management, analysis and interpretation of the data, publishing the data is the responsibility of the chief investigator, and the Collaborative Group. The funder does not have any role in the above.</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Availability of data and materials</title>
              <p>Following the publication of the main trial results anonymous data sets will be available on an individual case-by-case basis in accordance with the University of Birmingham, Birmingham Clinical Trials Unitâ€™s Standard Operating Procedures with agreement from Professor Catherine Sackley and Kingâ€™s College, London.</p>
            </notes>
            <notes id="FPar5">
              <title>Ethics approval and consent to participate</title>
              <p id="Par98">The trial received ethical approval from the West Midlands NHS Research Ethics Committee (15/WM/0443) prior to all trial activity in NHS sites. The ethical approval covers all participating centres. All participants in the trial will provide informed consent prior to any trial procedure.</p>
            </notes>
            <notes id="FPar6">
              <title>Consent for publication</title>
              <p id="Par99">Not applicable â€“ no individualâ€™s data is included.</p>
            </notes>
            <notes id="FPar7" notes-type="COI-statement">
              <title>Competing interests</title>
              <p id="Par100">The authors declare that they have no competing interests.</p>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <collab>Collaborators GBDPsD</collab>
                  </person-group>
                  <article-title>Global, regional, and national burden of Parkinsonâ€™s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016</article-title>
                  <source>Lancet Neurol</source>
                  <year>2018</year>
                  <volume>17</volume>
                  <issue>11</issue>
                  <fpage>939</fpage>
                  <lpage>953</lpage>
                  <pub-id pub-id-type="pmid">30287051</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kalia</surname>
                      <given-names>LV</given-names>
                    </name>
                    <name>
                      <surname>Lang</surname>
                      <given-names>AE</given-names>
                    </name>
                  </person-group>
                  <article-title>Parkinson's disease</article-title>
                  <source>Lancet</source>
                  <year>2015</year>
                  <volume>386</volume>
                  <issue>9996</issue>
                  <fpage>896</fpage>
                  <lpage>912</lpage>
                  <?supplied-pmid 25904081?>
                  <pub-id pub-id-type="pmid">25904081</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kalf</surname>
                      <given-names>JG</given-names>
                    </name>
                    <name>
                      <surname>de Swart</surname>
                      <given-names>BJ</given-names>
                    </name>
                    <name>
                      <surname>Bloem</surname>
                      <given-names>BR</given-names>
                    </name>
                    <name>
                      <surname>Munneke</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <source>Prevalence of speech impairments in Parkinsonâ€™s disease: a systematic review</source>
                  <year>2009</year>
                  <fpage>S528</fpage>
                  <lpage>S5S9</lpage>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Miller</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Allcock</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Jones</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Noble</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Hildreth</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Burn</surname>
                      <given-names>DJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Prevalence and pattern of perceived intelligibility changes in Parkinsonâ€™s disease</article-title>
                  <source>J Neurol Neurosurg Psychiatry</source>
                  <year>2007</year>
                  <volume>78</volume>
                  <issue>11</issue>
                  <fpage>1188</fpage>
                  <lpage>1190</lpage>
                  <?supplied-pmid 17400592?>
                  <pub-id pub-id-type="pmid">17400592</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hartelius</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Svensson</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Speech and swallowing symptoms associated with Parkinsonâ€™s disease and multiple sclerosis: a survey</article-title>
                  <source>Folia Phoniatr Logop</source>
                  <year>1994</year>
                  <volume>46</volume>
                  <issue>1</issue>
                  <fpage>9</fpage>
                  <lpage>17</lpage>
                  <?supplied-pmid 8162135?>
                  <pub-id pub-id-type="pmid">8162135</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Miller</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Noble</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Jones</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Burn</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Life with communication changes in Parkinsonâ€™s disease</article-title>
                  <source>Age Ageing</source>
                  <year>2006</year>
                  <volume>35</volume>
                  <issue>3</issue>
                  <fpage>235</fpage>
                  <lpage>239</lpage>
                  <?supplied-pmid 16540492?>
                  <pub-id pub-id-type="pmid">16540492</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pell</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Cheang</surname>
                      <given-names>HS</given-names>
                    </name>
                    <name>
                      <surname>Leonard</surname>
                      <given-names>CL</given-names>
                    </name>
                  </person-group>
                  <article-title>The impact of Parkinsonâ€™s disease on vocal-prosodic communication from the perspective of listeners</article-title>
                  <source>Brain Lang</source>
                  <year>2006</year>
                  <volume>97</volume>
                  <issue>2</issue>
                  <fpage>123</fpage>
                  <lpage>134</lpage>
                  <?supplied-pmid 16226803?>
                  <pub-id pub-id-type="pmid">16226803</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yorkston</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Baylor</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Britton</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Speech versus speaking: the experiences of people with Parkinsonâ€™s disease and implications for intervention</article-title>
                  <source>Am J Speech Lang Pathol</source>
                  <year>2017</year>
                  <volume>26</volume>
                  <issue>2S</issue>
                  <fpage>561</fpage>
                  <lpage>568</lpage>
                  <?supplied-pmid 28654939?>
                  <pub-id pub-id-type="pmid">28654939</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <mixed-citation publication-type="other">Heberlein I, Vieregge P. The influence of speech disturbances on quality of life and coping strategies on Parkinsonâ€™s disease patients. Forum Logopadie. 2005:19(3)26â€“31.</mixed-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Miller</surname>
                      <given-names>N</given-names>
                    </name>
                  </person-group>
                  <article-title>Communication changes in Parkinsonâ€™s disease</article-title>
                  <source>Pract Neurol</source>
                  <year>2017</year>
                  <volume>17</volume>
                  <issue>4</issue>
                  <fpage>266</fpage>
                  <lpage>274</lpage>
                  <?supplied-pmid 28687681?>
                  <pub-id pub-id-type="pmid">28687681</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ramig</surname>
                      <given-names>LO</given-names>
                    </name>
                    <name>
                      <surname>Sapir</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Fox</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Countryman</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Changes in vocal loudness following intensive voice treatment (LSVT) in individuals with Parkinsonâ€™s disease: a comparison with untreated patients and normal age-matched controls</article-title>
                  <source>Mov Disord</source>
                  <year>2001</year>
                  <volume>16</volume>
                  <issue>1</issue>
                  <fpage>79</fpage>
                  <lpage>83</lpage>
                  <?supplied-pmid 11215597?>
                  <pub-id pub-id-type="pmid">11215597</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Miller</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Deane</surname>
                      <given-names>KH</given-names>
                    </name>
                    <name>
                      <surname>Jones</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Noble</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Gibb</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>National survey of speech and language therapy provision for people with Parkinsonâ€™ disease in the United Kingdom: therapistsâ€™ practices</article-title>
                  <source>Int J Lang Commun Disord</source>
                  <year>2011</year>
                  <volume>46</volume>
                  <issue>2</issue>
                  <fpage>189</fpage>
                  <lpage>201</lpage>
                  <?supplied-pmid 21401817?>
                  <pub-id pub-id-type="pmid">21401817</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sackley</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>CH</given-names>
                    </name>
                    <name>
                      <surname>Rick</surname>
                      <given-names>CE</given-names>
                    </name>
                    <name>
                      <surname>Brady</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Ives</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Patel</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinsonâ€™s disease: a pilot randomised controlled trial (PD COMM pilot)</article-title>
                  <source>Pilot Feasibility Stud</source>
                  <year>2018</year>
                  <volume>4</volume>
                  <fpage>30</fpage>
                  <?supplied-pmid 29344405?>
                  <pub-id pub-id-type="pmid">29344405</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ramig</surname>
                      <given-names>LO</given-names>
                    </name>
                    <name>
                      <surname>Sapir</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Countryman</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Pawlas</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Oâ€™Brien</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Hoehn</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Intensive voice treatment (LSVT) for patients with Parkinsonâ€™s disease: a 2 year follow up</article-title>
                  <source>J Neurol Neurosurg Psychiatry</source>
                  <year>2001</year>
                  <volume>71</volume>
                  <issue>4</issue>
                  <fpage>493</fpage>
                  <lpage>498</lpage>
                  <?supplied-pmid 11561033?>
                  <pub-id pub-id-type="pmid">11561033</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Herd</surname>
                      <given-names>CP</given-names>
                    </name>
                    <name>
                      <surname>Tomlinson</surname>
                      <given-names>CL</given-names>
                    </name>
                    <name>
                      <surname>Deane</surname>
                      <given-names>KH</given-names>
                    </name>
                    <name>
                      <surname>Brady</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>CH</given-names>
                    </name>
                    <name>
                      <surname>Sackley</surname>
                      <given-names>CM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Speech and language therapy versus placebo or no intervention for speech problems in Parkinsonâ€™s disease</article-title>
                  <source>Cochrane Database Syst Rev</source>
                  <year>2012</year>
                  <volume>8</volume>
                  <fpage>CD002812</fpage>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Johnson</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Pring</surname>
                      <given-names>TR</given-names>
                    </name>
                  </person-group>
                  <article-title>Speech therapy and Parkinsonâ€™s disease: a review and further data</article-title>
                  <source>Br J Disord Commun</source>
                  <year>1990</year>
                  <volume>25</volume>
                  <issue>2</issue>
                  <fpage>183</fpage>
                  <lpage>194</lpage>
                  <?supplied-pmid 2206966?>
                  <pub-id pub-id-type="pmid">2206966</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Robertson</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <name>
                      <surname>Thomson</surname>
                      <given-names>F</given-names>
                    </name>
                  </person-group>
                  <article-title>Speech therapy in Parkinsonâ€™s disease: a study of the efficacy and long term effects of intensive treatment</article-title>
                  <source>Br J Disord Commun.</source>
                  <year>1984</year>
                  <volume>19</volume>
                  <issue>3</issue>
                  <fpage>213</fpage>
                  <lpage>224</lpage>
                  <?supplied-pmid 6508992?>
                  <pub-id pub-id-type="pmid">6508992</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Herd</surname>
                      <given-names>CP</given-names>
                    </name>
                    <name>
                      <surname>Tomlinson</surname>
                      <given-names>CL</given-names>
                    </name>
                    <name>
                      <surname>Deane</surname>
                      <given-names>KH</given-names>
                    </name>
                    <name>
                      <surname>Brady</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>CH</given-names>
                    </name>
                    <name>
                      <surname>Sackley</surname>
                      <given-names>CM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Comparison of speech and language therapy techniques for speech problems in Parkinsonâ€™s disease</article-title>
                  <source>Cochrane Database Syst Rev</source>
                  <year>2012</year>
                  <volume>8</volume>
                  <fpage>CD002814</fpage>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Halpern</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Spielman</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Ramig</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Cable</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Panzer</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Sharpley</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>The effects of loudness and noise on speech intelligibility in Parkinson's disease</article-title>
                  <source>Mov Disord</source>
                  <year>2007</year>
                  <volume>22</volume>
                  <issue>16</issue>
                  <fpage>S105</fpage>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ramig</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Halpern</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Spielman</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Fox</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Freeman</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <article-title>Speech treatment in Parkinsonâ€™s disease: randomized controlled trial (RCT)</article-title>
                  <source>Mov Disord</source>
                  <year>2018</year>
                  <volume>33</volume>
                  <issue>11</issue>
                  <fpage>1777</fpage>
                  <lpage>1791</lpage>
                  <?supplied-pmid 30264896?>
                  <pub-id pub-id-type="pmid">30264896</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chan</surname>
                      <given-names>AW</given-names>
                    </name>
                    <name>
                      <surname>Tetzlaff</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Altman</surname>
                      <given-names>DG</given-names>
                    </name>
                    <name>
                      <surname>Laupacis</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Gotzsche</surname>
                      <given-names>PC</given-names>
                    </name>
                    <name>
                      <surname>Krleza-Jeric</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>SPIRIT 2013 Statement: defining standard protocol items for clinical trials</article-title>
                  <source>Ann Intern Med</source>
                  <year>2013</year>
                  <volume>158</volume>
                  <issue>3</issue>
                  <fpage>200</fpage>
                  <lpage>207</lpage>
                  <?supplied-pmid 5114123?>
                  <pub-id pub-id-type="pmid">23295957</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hoffmann</surname>
                      <given-names>TC</given-names>
                    </name>
                    <name>
                      <surname>Glasziou</surname>
                      <given-names>PP</given-names>
                    </name>
                    <name>
                      <surname>Boutron</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Milne</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Perera</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Moher</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Better reporting of interventions: Template for Intervention Description and Replication (TIDieR) checklist and guide</article-title>
                  <source>BMJ</source>
                  <year>2014</year>
                  <volume>348</volume>
                  <fpage>g1687</fpage>
                  <?supplied-pmid 24609605?>
                  <pub-id pub-id-type="pmid">24609605</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gibb</surname>
                      <given-names>WR</given-names>
                    </name>
                    <name>
                      <surname>Lees</surname>
                      <given-names>AJ</given-names>
                    </name>
                  </person-group>
                  <article-title>The relevance of the Lewy body to the pathogenesis of idiopathic Parkinsonâ€™s disease</article-title>
                  <source>J Neurol Neurosurg Psychiatry</source>
                  <year>1988</year>
                  <volume>51</volume>
                  <issue>6</issue>
                  <fpage>745</fpage>
                  <lpage>752</lpage>
                  <?supplied-pmid 2841426?>
                  <pub-id pub-id-type="pmid">2841426</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hoehn</surname>
                      <given-names>MM</given-names>
                    </name>
                    <name>
                      <surname>Yahr</surname>
                      <given-names>MD</given-names>
                    </name>
                  </person-group>
                  <article-title>Parkinsonism: onset, progression and mortality</article-title>
                  <source>Neurology</source>
                  <year>1967</year>
                  <volume>17</volume>
                  <issue>5</issue>
                  <fpage>427</fpage>
                  <lpage>442</lpage>
                  <pub-id pub-id-type="pmid">6067254</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jacobson</surname>
                      <given-names>BH</given-names>
                    </name>
                    <name>
                      <surname>Johnson</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Grywalski</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The Voice Handicap Index (VHI): development and validation</article-title>
                  <source>Am J Speech Lang Pathol</source>
                  <year>1997</year>
                  <volume>6</volume>
                  <fpage>66</fpage>
                  <lpage>70</lpage>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Scott</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Caird</surname>
                      <given-names>FI</given-names>
                    </name>
                  </person-group>
                  <article-title>Speech therapy for Parkinsonâ€™s disease</article-title>
                  <source>J Neurol Neurosurg Psychiatry</source>
                  <year>1983</year>
                  <volume>46</volume>
                  <issue>2</issue>
                  <fpage>140</fpage>
                  <lpage>144</lpage>
                  <?supplied-pmid 6842217?>
                  <pub-id pub-id-type="pmid">6842217</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Scott</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Caird</surname>
                      <given-names>FI</given-names>
                    </name>
                  </person-group>
                  <article-title>The response of the apparent receptive speech disorder of Parkinsonâ€™s disease to speech therapy</article-title>
                  <source>J Neurol Neurosurg Psychiatry</source>
                  <year>1984</year>
                  <volume>47</volume>
                  <issue>3</issue>
                  <fpage>302</fpage>
                  <lpage>304</lpage>
                  <?supplied-pmid 6707678?>
                  <pub-id pub-id-type="pmid">6707678</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Scott</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Caird</surname>
                      <given-names>FI</given-names>
                    </name>
                  </person-group>
                  <article-title>Speech therapy for patients with Parkinsonâ€™s disease</article-title>
                  <source>BMJ (Clin Res Ed)</source>
                  <year>1981</year>
                  <volume>283</volume>
                  <issue>6299</issue>
                  <fpage>1088</fpage>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lang</surname>
                      <given-names>AE</given-names>
                    </name>
                    <name>
                      <surname>Fishbein</surname>
                      <given-names>V</given-names>
                    </name>
                  </person-group>
                  <article-title>The â€˜pacing boardâ€™ in selected speech disorders of Parkinsonâ€™s disease</article-title>
                  <source>J Neurol Neurosurg Psychiatry</source>
                  <year>1983</year>
                  <volume>46</volume>
                  <issue>8</issue>
                  <fpage>789</fpage>
                  <?supplied-pmid 6886727?>
                  <pub-id pub-id-type="pmid">6886727</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <mixed-citation publication-type="other">Healey V. A comparison of the efficacy of two methods of rate control in the speech of people with Parkinsonâ€™s disease. Parkinsonâ€™s News: A Quarterly Bulletin for Health and Social Care Professionals; 2006. p. 6â€“7.</mixed-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hustad</surname>
                      <given-names>KC</given-names>
                    </name>
                  </person-group>
                  <article-title>The relationship between listener comprehension and intelligibility scores for speakers with dysarthria</article-title>
                  <source>J Speech Lang Hear Res</source>
                  <year>2008</year>
                  <volume>51</volume>
                  <issue>3</issue>
                  <fpage>562</fpage>
                  <lpage>573</lpage>
                  <?supplied-pmid 18506035?>
                  <pub-id pub-id-type="pmid">18506035</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Adams</surname>
                      <given-names>SG</given-names>
                    </name>
                    <name>
                      <surname>Lang</surname>
                      <given-names>AE</given-names>
                    </name>
                  </person-group>
                  <article-title>Can the Lombard effect be used to improve low voice intensity in Parkinsonâ€™s disease?</article-title>
                  <source>Eur J Disord Commun</source>
                  <year>1992</year>
                  <volume>27</volume>
                  <issue>2</issue>
                  <fpage>121</fpage>
                  <lpage>127</lpage>
                  <?supplied-pmid 1446099?>
                  <pub-id pub-id-type="pmid">1446099</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schulz</surname>
                      <given-names>GM</given-names>
                    </name>
                    <name>
                      <surname>Grant</surname>
                      <given-names>MK</given-names>
                    </name>
                  </person-group>
                  <article-title>Effects of speech therapy and pharmacologic and surgical treatments on voice and speech in Parkinsonâ€™s disease: a review of the literature</article-title>
                  <source>J Commun Disord</source>
                  <year>2000</year>
                  <volume>33</volume>
                  <issue>1</issue>
                  <fpage>59</fpage>
                  <lpage>88</lpage>
                  <?supplied-pmid 10665513?>
                  <pub-id pub-id-type="pmid">10665513</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rousseau</surname>
                      <given-names>BWC</given-names>
                    </name>
                  </person-group>
                  <article-title>Susceptibility of speakers with Parkinson disease to delayed feedback</article-title>
                  <source>J Med Speech Lang Pathol</source>
                  <year>2002</year>
                  <volume>10</volume>
                  <fpage>41</fpage>
                  <lpage>49</lpage>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>de Swart</surname>
                      <given-names>BJ</given-names>
                    </name>
                    <name>
                      <surname>Willemse</surname>
                      <given-names>SC</given-names>
                    </name>
                    <name>
                      <surname>Maassen</surname>
                      <given-names>BA</given-names>
                    </name>
                    <name>
                      <surname>Horstink</surname>
                      <given-names>MW</given-names>
                    </name>
                  </person-group>
                  <article-title>Improvement of voicing in patients with Parkinsonâ€™s disease by speech therapy</article-title>
                  <source>Neurology</source>
                  <year>2003</year>
                  <volume>60</volume>
                  <issue>3</issue>
                  <fpage>498</fpage>
                  <lpage>500</lpage>
                  <?supplied-pmid 12578936?>
                  <pub-id pub-id-type="pmid">12578936</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ramig</surname>
                      <given-names>LO</given-names>
                    </name>
                    <name>
                      <surname>Countryman</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Thompson</surname>
                      <given-names>LL</given-names>
                    </name>
                    <name>
                      <surname>Horii</surname>
                      <given-names>Y</given-names>
                    </name>
                  </person-group>
                  <article-title>Comparison of two forms of intensive speech treatment for Parkinson disease</article-title>
                  <source>J Speech Hear Res</source>
                  <year>1995</year>
                  <volume>38</volume>
                  <issue>6</issue>
                  <fpage>1232</fpage>
                  <lpage>1251</lpage>
                  <?supplied-pmid 8747817?>
                  <pub-id pub-id-type="pmid">8747817</pub-id>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Spielman</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Ramig</surname>
                      <given-names>LO</given-names>
                    </name>
                    <name>
                      <surname>Mahler</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Halpern</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Gavin</surname>
                      <given-names>WJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Effects of an extended version of the Lee Silverman voice treatment on voice and speech in Parkinsonâ€™s disease</article-title>
                  <source>Am J Speech Lang Pathol</source>
                  <year>2007</year>
                  <volume>16</volume>
                  <issue>2</issue>
                  <fpage>95</fpage>
                  <lpage>107</lpage>
                  <?supplied-pmid 17456888?>
                  <pub-id pub-id-type="pmid">17456888</pub-id>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Krohling</surname>
                      <given-names>LL</given-names>
                    </name>
                    <name>
                      <surname>Paula</surname>
                      <given-names>KM</given-names>
                    </name>
                    <name>
                      <surname>Behlau</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>ROC curve of the Pediatric Voice Related Quality-of-Life Survey (P-VRQOL)</article-title>
                  <source>Codas</source>
                  <year>2016</year>
                  <volume>28</volume>
                  <issue>3</issue>
                  <fpage>311</fpage>
                  <lpage>313</lpage>
                  <?supplied-pmid 27253227?>
                  <pub-id pub-id-type="pmid">27253227</pub-id>
                </element-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jenkinson</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Fitzpatrick</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Peto</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Greenhall</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Hyman</surname>
                      <given-names>N</given-names>
                    </name>
                  </person-group>
                  <article-title>The Parkinsonâ€™s Disease Questionnaire (PDQ-39): development and validation of a Parkinsonâ€™s disease summary index score</article-title>
                  <source>Age Ageing</source>
                  <year>1997</year>
                  <volume>26</volume>
                  <issue>5</issue>
                  <fpage>353</fpage>
                  <lpage>357</lpage>
                  <?supplied-pmid 9351479?>
                  <pub-id pub-id-type="pmid">9351479</pub-id>
                </element-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hartelius</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Elmberg</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Holm</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Lovberg</surname>
                      <given-names>AS</given-names>
                    </name>
                    <name>
                      <surname>Nikolaidis</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Living with dysarthria: evaluation of a self-report questionnaire</article-title>
                  <source>Folia Phoniatr Logop</source>
                  <year>2008</year>
                  <volume>60</volume>
                  <issue>1</issue>
                  <fpage>11</fpage>
                  <lpage>19</lpage>
                  <?supplied-pmid 18057906?>
                  <pub-id pub-id-type="pmid">18057906</pub-id>
                </element-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Herdman</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Gudex</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Lloyd</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Janssen</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kind</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Parkin</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)</article-title>
                  <source>Qual Life Res</source>
                  <year>2011</year>
                  <volume>20</volume>
                  <issue>10</issue>
                  <fpage>1727</fpage>
                  <lpage>1736</lpage>
                  <?supplied-pmid 3220807?>
                  <pub-id pub-id-type="pmid">21479777</pub-id>
                </element-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Coast</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Flynn</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Sutton</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Al-Janabi</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Vosper</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Lavender</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Investigating Choice Experiments for Preferences of Older People (ICEPOP): evaluative spaces in health economics</article-title>
                  <source>J Health Serv Res Policy</source>
                  <year>2008</year>
                  <volume>13</volume>
                  <issue>Suppl 3</issue>
                  <fpage>31</fpage>
                  <lpage>37</lpage>
                  <?supplied-pmid 18806190?>
                  <pub-id pub-id-type="pmid">18806190</pub-id>
                </element-citation>
              </ref>
              <ref id="CR43">
                <label>43.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jenkinson</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Dummett</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Kelly</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Peters</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Dawson</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Morley</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The development and validation of a quality of life measure for the carers of people with Parkinsonâ€™s disease (the PDQ-Carer)</article-title>
                  <source>Parkinsonism Relat Disord</source>
                  <year>2012</year>
                  <volume>18</volume>
                  <issue>5</issue>
                  <fpage>483</fpage>
                  <lpage>487</lpage>
                  <?supplied-pmid 22321866?>
                  <pub-id pub-id-type="pmid">22321866</pub-id>
                </element-citation>
              </ref>
              <ref id="CR44">
                <label>44.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hodkinson</surname>
                      <given-names>HM</given-names>
                    </name>
                  </person-group>
                  <article-title>Evaluation of a mental test score for assessment of mental impairment in the elderly. 1972</article-title>
                  <source>Age Ageing</source>
                  <year>2012</year>
                  <volume>41</volume>
                  <issue>Suppl 3</issue>
                  <fpage>iii35</fpage>
                  <lpage>iii40</lpage>
                  <?supplied-pmid 23144286?>
                  <pub-id pub-id-type="pmid">23144286</pub-id>
                </element-citation>
              </ref>
              <ref id="CR45">
                <label>45.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Masterson-Algar</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Burton</surname>
                      <given-names>CR</given-names>
                    </name>
                    <name>
                      <surname>Brady</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Nicoll</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Clarke</surname>
                      <given-names>CE</given-names>
                    </name>
                    <name>
                      <surname>Rick</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The PD COMM trial: a protocol for the process evaluation of a randomised trial assessing the effectiveness of two types of SLT for people with Parkinsonâ€™s disease</article-title>
                  <source>Trials</source>
                  <year>2017</year>
                  <volume>18</volume>
                  <issue>1</issue>
                  <fpage>397</fpage>
                  <?supplied-pmid 28851443?>
                  <pub-id pub-id-type="pmid">28851443</pub-id>
                </element-citation>
              </ref>
              <ref id="CR46">
                <label>46.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Curtis</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Burns</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <source>Unit Costs of Health and Social Care 2017: Personal Social Services Research Unit, University of Kent</source>
                  <year>2018</year>
                </element-citation>
              </ref>
              <ref id="CR47">
                <label>47.</label>
                <mixed-citation publication-type="other">2017/2018 DoHNRC. London. 2018. <ext-link ext-link-type="uri" xlink:href="https://improvement.nhs.uk/resources/reference-costs">https://improvement.nhs.uk/resources/reference-costs</ext-link>. Accessed 20 May 2019.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
